RA Capital Healthcare Fund LP 的 Form 4 申報
Climb Bio, Inc.（CLYM），2025/12/15 申報
- 申報編號
- 0001231919-25-000616
- 申報時間
- 2025/12/15 19:55 ET
- 交易日
- 2025/12/11-12/12
- 申報延遲
- 4 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 3 筆非衍生性交易、1 筆衍生性交易。公開市場買進合計 $75.5 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| RA Capital Healthcare Fund LPCIK 0001315082 | 董事、持股 10% 以上大股東 |
| Ra Capital Management, L.P.CIK 0001346824 | 董事、持股 10% 以上大股東 |
| Kolchinsky PeterCIK 0001384859 | 董事、持股 10% 以上大股東 |
| Shah Rajeev M.CIK 0001619841 | 董事、持股 10% 以上大股東 |
| RA Capital Nexus Fund, L.P.CIK 0001780117 | 董事 |
| RA Capital Nexus Fund II, L.P.CIK 0001825376 | 董事 |
| RA Capital Nexus Fund III, L.P.CIK 0001883840 | 董事、持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/12/11 | Common Stock | A公司授予取得 | +20,440,000 | –F1 | – | 20,440,000 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
On December 11, 2025, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 20,440,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 20,440,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share.
表 II 有 1 筆交易的價格引用這則附註。
- F4
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.11 to $2.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.32 to $3.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
備註
Dr. Andrew Levin, a Partner and Managing Director of the Adviser, serves on the Issuer's board of directors.